Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Prepaid Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Prepaid Assets for 7 consecutive years, with $7.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets fell 17.5% to $7.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.3 million, a 17.5% decrease, with the full-year FY2024 number at $10.1 million, up 20.33% from a year prior.
  • Prepaid Assets was $7.3 million for Q3 2025 at 4D Molecular Therapeutics, down from $10.1 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $11.1 million in Q1 2025 to a low of $3.3 million in Q3 2021.
  • A 5-year average of $7.5 million and a median of $7.4 million in 2023 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: skyrocketed 90.28% in 2021, then decreased 17.73% in 2022.
  • 4D Molecular Therapeutics' Prepaid Assets stood at $8.5 million in 2021, then decreased by 17.73% to $7.0 million in 2022, then grew by 20.11% to $8.4 million in 2023, then increased by 20.33% to $10.1 million in 2024, then decreased by 27.26% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Prepaid Assets are $7.3 million (Q3 2025), $10.1 million (Q2 2025), and $11.1 million (Q1 2025).